Table 3.

Association between KCCQ Categorical Change Groups at 3 Months and Study Outcomes (Reference = No change [<5 point group])

		Unadjusted		Adjusted for Baseline KCCQ		Adjusted for Clinical Variables
Outcome		HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
All-cause mortality or all-cause hospitalization
KCCQ	No change (<5 point)	Reference		Reference		Reference
	Decrease (≥ 5 point)	1.33 (1.11, 1.60)	0.002	1.28 (1.07, 1.54)	0.008	1.19 (0.99, 1.43)*	0.07
	Increase (≥5 point)	1.0 (0.86, 1.17)	0.99	0.84 (0.71, 0.99)	0.04	0.88 (0.74, 1.04)*	0.12
All-cause mortality
KCCQ	No change (<5 point)	Reference		Reference		Reference
	Decrease (≥ 5 point)	1.39 (1.04, 1.86)	0.03	1.37 (1.03, 1.84)	0.03	1.26 (0.94, 1.69) †	0.12
	Increase (≥5 point)	0.97 (0.74, 1.26)	0.80	0.81 (0.61, 1.06)	0.12	0.87 (0.66, 1.15) †	0.33
Cardiovascular mortality or heart failure hospitalization
KCCQ	No change (<5 point)	Reference		Reference		Reference
	Decrease (≥ 5 point)	1.42 (1.11, 1.82)	0.006	1.39 (1.09, 1.79)	0.009	1.36 (1.06, 1.76)‡	0.02
	Increase (≥5 point)	1.01 (0.81, 1.26)	0.95	0.83 (0.66, 1.05)	0.12	0.88 (0.70, 1.11)‡	0.29

^*Model for all-cause mortality or all-cause hospitalization adjusted for baseline KCCQ score, randomized treatment assignment, dosage of beta-blocker, KCCQ symptom stability, ejection fraction (LVEF), country (US vs non-US), sex, ventricular conduction, Weber class, blood urea nitrogen (BUN), and mitral regurgitation.

^†Model of all-cause mortality adjusted for baseline KCCQ score, randomized treatment assignment, sex, body mass index, loop diuretic dose, creatinine, exercise duration, ventricular conduction, Canadian Cardiovascular Society angina classification, and LVEF.

^‡Model for cardiovascular mortality or heart failure hospitalization adjusted for baseline KCCQ score, randomized treatment assignment, loop diuretic dose, LVEF, mitral regurgitation, ventricular conduction, KCCQ symptom stability, BUN, race, sex, age, Weber class, VE/VCO₂.